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NPH to insulin glargine and combining the effect of HbA1c and
hypoglycaemia reduction. METHODS: A discrete event life time
simulation with microvascular complications incorporated via
the DCCT (Diabetes Control and Complications Trial) study and
cardiovascular events modelled using the Framingham equations
was adapted to include the combined effects of HbA1c and
hypoglycaemia reduction using published meta-regression results
from 11 randomised clinical trials. Direct costs and quality of life
(EQ5D) were derived from published sources and the HODaR
database respectively; costs and beneﬁts were discounted annu-
ally at 3.5%. The model was adapted to the proﬁle of T1DM
patients switched from NPH to glargine identiﬁed via the THIN
database. Analysis was conducted on a total of 383 patients with
data for the 12 month period prior to, and post switch; using
primary outcome measure of adjusted Hba1c change. As
hypoglycaemia was not directly collected from the THIN data-
base a sensitivity analysis was performed taking into account
HbA1c beneﬁt only. RESULTS: The median age of patients
switched from NPH to glargine was 34 years with mean duration
of T1DM of 11.4 years. Baseline HbA1c was 8.71% and patients
switching to glargine showed a reduction in HbA1c of 0.195%
(p = 0.0045) between switch and 12-months post initiation. In a
simulated cohort of 10,000 the discounted incremental cost
effectiveness ratio (ICER) was 3,665 per quality adjusted life
year gained (QALY). In sensitivity analysis using HbA1c beneﬁt
only the ICER was 9,411. CONCLUSION: Based on real life
observational data, switching to glargine is cost-effective when
compared to NPH; with a corresponding ICER well within
accepted thresholds, even in sensitivity analysis using HbA1c
effect only.
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OBJECTIVES: In a multinational, multicenter, observational
study (PRESENT), patients treated with human premix insulin
(with or without conventional oral medication) were converted
to biphasic insulin aspart 30 (BIAsp 30) whilst maintaining their
existing oral therapy. A sub-analysis (involving 1219 patients)
demonstrated an improvement six months after therapy conver-
sion of 1.66%-point in HbA1c and a reduced rate of hypoglyce-
mic events (1079.8 to 290.2 per 100 patient years). METHODS:
The published and validated CORE Diabetes Model was used to
make long-term projections of clinical and cost outcomes based
on patient characteristics (mean age 56.8 years, duration of
diabetes 10.2 years, HbA1c 9.1%, BMI 28.7 kg.m-2) and treat-
ment effects from PRESENT. Spanish mortality rates, baseline
complications and costs of treating complications were derived
from published sources. Transition probabilities were based on
data from landmark clinical and epidemiological studies. Total
direct costs (complications + treatment costs) were projected
over patient lifetimes from a Spanish health care payer’s perspec-
tive with future costs and clinical beneﬁts discounted at 3.5%
annually. RESULTS: Long-term projections indicated that BIAsp
30 treatment was associated with an improvement in discounted
life expectancy of 0.77 years (11.33  0.15 versus 10.57  0.14
years). Taking quality of life into account led to a projected
improvement of 1.03 quality-adjusted life years (QALYs) with
BIAsp 30 over human premix insulin (7.83  0.11 versus
6.80  0.09 QALYs). Superior glycemic control associated with
BIAsp 30 treatment was also projected to lead to fewer diabetes-
related complications and a net reduction in total direct medical
costs of €8339 (€32,107  1030 versus €40,446  1247). CON-
CLUSION: Higher pharmacy costs associated with BIAsp 30
treatment were offset by savings in the costs associated with
diabetes-related complications versus human premix insulin.
This resulted in a dominant scenario, where BIAsp 30 was asso-
ciated with improved clinical outcomes and reduced costs com-
pared to human premix insulin in the Spanish setting.
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OBJECTIVES: An internal study showed the relative risk of
stroke was 0.800 and of MI was 0.621 for PIO based therapies
versus non-TZD. Reduced MI and stroke events may drive
reduced health care costs. Our objective was to compare health
care costs in T2DM patients treated with PIO based versus
non-TZD based therapies who had no prior MI or stroke events.
METHODS: A retrospective cohort analysis was conducted
using US health plan data (I3Innovus) from January 1, 2003 to
June 30, 2006. Initial ICD-9 codes for T2DM (250.x0 and
250.x2) deﬁned patient index date. The PIO group included
patients treated with PIO combined with any other antidiabetic
agents (excluding rosiglitazone). The non-TZD group included
patients treated with any antidiabetic treatment, but not TZDs.
Inclusion criteria were: age45 years, continuous enrollment for
at least 6 months before and 1 month after the index date, no
history of stroke or MI in the last six months and documented
medical claims after the index date. Stroke and MI were deﬁned
by appropriate ICD-9 codes. We ﬁtted a generalized linear model
with log link and gamma distribution to the monthly average
cost in 1] stroke and [2] MI cohorts, controlling for age, hyper-
tension, and hypercholesteremia. RESULTS: In the stroke cohort,
mean total health care cost per patient per month was $1,839 in
the PIO group versus $2,115 in the non-TZD group
(p < 0.0001). In the MI cohort, mean total health care cost per
patient per month was $1,843 in the PIO group versus $2,191 in
the non-TZD group (p < 0.0001). Mean medical cost per patient
per month in the stroke and MI cohorts was 20% and 23% less,
respectively, in the PIO group compared to the non-TZD group.
CONCLUSION: PIO based therapies are associated with signiﬁ-
cantly lower medical and total health care costs compared to
those not treated with TZDs in MI and stroke cohorts.
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OBJECTIVES: Data from the PREDICTIVE study indicated
that, in type 2 diabetes patients receiving long-acting insulin
therapy  oral hypoglycemic agents (OHAs), therapy conversion
from insulin glargine to insulin detemir was associated with
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signiﬁcant improvements in glycemic control (HbA1c 0.59%)
and body weight (BMI 0.52 kg.m-2). The aim of this analysis
was to estimate the long-term clinical and cost implications asso-
ciated with therapy conversion from insulin glargine to detemir
in type 2 diabetes patients in Germany. METHODS: A previ-
ously published and validated diabetes model (CORE Diabetes
Model) was used to make long-term projections of clinical and
cost outcomes based on patient characteristics (age 62.3 years,
duration of diabetes 7 years, HbA1c 8.30%, 50.4% male) and
treatment effects from the German part of PREDICTIVE. The
model was used to estimate life-expectancy, quality-adjusted life
expectancy and to account direct medical costs (pharmacy,
patient management and complication costs). Costs were derived
from published sources and expressed in 2006 Euros. Future
costs and clinical beneﬁts were discounted at 5% annually.
RESULTS: Therapy conversion from insulin glargine to insulin
detemir was projected to improve life expectancy by approxi-
mately 0.13 years (7.08  0.13 versus 6.95  0.12 years) and
quality-adjusted life expectancy by 0.29 quality-adjusted life
years (QALYs) (4.53  0.09 versus 4.24  0.08 QALYs). Direct
costs associated with insulin detemir treatment were projected
to be lower over patient lifetimes than with glargine (€
54,807  1,788 versus € 55,839  1,749 per patient, difference
€ 1,032). Cost savings were driven by lower complication costs
(due to HbA1c improvements) associated with insulin detemir.
CONCLUSION: Modeling the long-term implications of therapy
conversion from insulin glargine to detemir based on data from
German patients in PREDICTIVE indicates that insulin detemir
is associated with beneﬁts in terms of life expectancy, quality-
adjusted life expectancy and complication rates, as well as reduc-
ing costs from a third-party health care payer perspective in
Germany.
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OBJECTIVES: To assess the costs and effects of Januvia versus
Avandia as supplementary treatment in combination with met-
formin, for patients with type 2 diabetes in whom metformin (in
addition to diet and exercise) does not provide adequate glycemic
control. METHODS: The Disease Elimination Life Table Analy-
sis (DELTA) cohort model was used to assess the costs and effects
of Januvia (100 mg) in comparison to Avandia (8 mg). The
model contains ﬁve sub models representing diabetes related
complications. Estimates of disease progression, incidence in the
sub models, disease related mortality, and all cause mortality,
were derived from the UK Prospective Diabetes Study. Estimates
regarding drug efﬁcacy and adverse events were based on an
18-week head-to-head comparison of Januvia 100 mg versus
Avandia 8 mg supplementary to metformin. The analysis was
conducted from a societal perspective. Direct and indirect costs
were included. Effects were reported as (disease-free) life years
and quality-adjusted life years (QALY). To determine the robust-
ness of the model and the impact of uncertainty, uni- and mul-
tivariate sensitivity analyses were carried out. RESULTS: Januvia
is estimated to be the dominant treatment when compared to
Avandia 8 mg. The univariate sensitivity analyses revealed this
conclusion to be robust over a wide range of values. Results from
the multivariate sensitivity analysis estimate the probability that
Januvia combines additional effectiveness with cost savings at
59%, the probability that Januvia gains QALYs at additional
costs at 13%. The probability that Januvia is less effective is
estimated at 28% (15% with cost savings and in 13% with
additional costs). CONCLUSION: Conditional on the correct-
ness of the estimates and assumptions made, Januvia 100 mg is
dominant over 8 mg Avandia. Sensitivity analyses suggest results
are robust to reasonable changes in input parameters.
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OBJECTIVES: The aim of this analysis was to project the long-
term clinical and economic outcomes associated with therapy
conversion to insulin detemir from Neutral Protamine Hagedorn
(NPH) insulin in patients with type 2 diabetes in the German
setting. METHODS: A previously published and validated com-
puter simulation model of diabetes was used to make long-term
projections of clinical and cost outcomes based on patient char-
acteristics and treatment effects from a sub-analysis of the PRE-
DICTIVE study. Data from PREDICTIVE indicated that therapy
conversion from NPH insulin to insulin detemir was associated
with signiﬁcant improvements in glycemic control (HbA1c
-0.6%) and reduced weight gain (body mass index -0.382 kg/
m2). Based on these clinical ﬁndings, the computer simulation
model was used to estimate life-expectancy, quality-adjusted life
expectancy and costs from a third party healthcare payer per-
spective. Future costs and clinical beneﬁts were discounted at 5%
per annum. RESULTS: Conversion to insulin detemir was pro-
jected to improve life expectancy by approximately 0.13 years
compared to NPH (7.08  0.13 versus 6.95  0.12 years) and
quality-adjusted life expectancy by 0.28 quality-adjusted life
years (QALYs) (4.51  0.09 versus 4.23  0.08 QALYs). Direct
medical costs over patient lifetimes were projected to be margin-
ally lower in patients receiving insulin detemir compared to NPH
(€ 54,575  1,842 versus € 54,640  1,739, difference € 65 per
patient). Pharmacy costs were higher with insulin detemir
(€ 14,129 versus € 12,230, difference € 1,899) but were more
than offset by cost savings due to complications avoided (com-
plication costs € 38,246 versus € 40,242, difference € 1,996).
CONCLUSIONS: This modeling study, based on a German sub-
analysis of PREDICTIVE, suggests that therapy conversion from
NPH to insulin detemir is likely to be associated with long-term
clinical beneﬁts and may well be cost saving in type 2 diabetes
patients in the German setting.
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OBJECTIVES: Based on the clinical results of the LAPTOP trial,
a cost analysis from the perspective of the German Statutory
Health Insurance (SHI) was performed. In addition a model
simulation of the long term complications was conducted using
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